198 related articles for article (PubMed ID: 15329909)
61. A personal history of the CAMPATH-1H antibody.
Waldmann H
Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
[TBL] [Abstract][Full Text] [Related]
62. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
63. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor VC; Sims M; Brett S; Field MC
Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
[TBL] [Abstract][Full Text] [Related]
64. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
65. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract][Full Text] [Related]
66. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
67. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
68. Monoclonal antibody therapy of leukaemias and lymphomas.
Jacobs SA; Foon KA
Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
[TBL] [Abstract][Full Text] [Related]
69. Expression of CD52 on plasma cells in plasma cell proliferative disorders.
Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE
Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489
[TBL] [Abstract][Full Text] [Related]
70. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
71. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
Jaglowski SM; Alinari L; Lapalombella R; Muthusamy N; Byrd JC
Blood; 2010 Nov; 116(19):3705-14. PubMed ID: 20610811
[TBL] [Abstract][Full Text] [Related]
72. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE
Leuk Res; 2008 Dec; 32(12):1849-56. PubMed ID: 18584865
[TBL] [Abstract][Full Text] [Related]
73. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
[TBL] [Abstract][Full Text] [Related]
74. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
75. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
76. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
77. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
Ambrose LR; Morel AS; Warrens AN
Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623
[TBL] [Abstract][Full Text] [Related]
78. Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study.
Janker S; Doswald S; Schimmer RR; Schanz U; Stark WJ; Schläpfer M; Beck-Schimmer B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108680
[TBL] [Abstract][Full Text] [Related]
79. Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
Tembhare PR; Marti G; Wiestner A; Degheidy H; Farooqui M; Kreitman RJ; Jasper GA; Yuan CM; Liewehr D; Venzon D; Stetler-Stevenson M
Am J Clin Pathol; 2013 Dec; 140(6):813-8. PubMed ID: 24225748
[TBL] [Abstract][Full Text] [Related]
80. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
